Six recent listings, six very different starts.
From Apnimed (APMD), up roughly 98% from its IPO price, to Lyntris (LYNX), still trading below its offer, our Friday IPO Review examines the businesses, post-listing performance, key catalysts and risks behind APMD, ATTO, BRVE, BLSM, LTGO and LYNX.
What we look at
Each name gets the same treatment: what the company actually sells, how the stock has traded since listing, what could move it next, and what could go wrong. The aim is a sober read on valuations after the debut noise, not a scoreboard.
The full review is available to TFOS clients, and the conversation continues on our LinkedIn page.
Marketing communication, not independent investment research and not financial advice. Past performance is not a guide to future results. Turlov Family Office Securities (Pty) Ltd is an authorised FSP (52874).